The Cognitive Footprint of Medication Use
ABSTRACT Introduction The cognitive side‐effects of medication are common, but often overlooked in practice, and not routinely considered in interventional trials or post‐market surveillance. The cognitive footprint of a medication seeks to quantify the impact of its cognitive effects based on magni...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.70200 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582645311078400 |
|---|---|
| author | Marta Suárez Pinilla Charlotte R. Stoner Martin Knapp Parashkev Nachev Martin Rossor |
| author_facet | Marta Suárez Pinilla Charlotte R. Stoner Martin Knapp Parashkev Nachev Martin Rossor |
| author_sort | Marta Suárez Pinilla |
| collection | DOAJ |
| description | ABSTRACT Introduction The cognitive side‐effects of medication are common, but often overlooked in practice, and not routinely considered in interventional trials or post‐market surveillance. The cognitive footprint of a medication seeks to quantify the impact of its cognitive effects based on magnitude, duration, and interaction with other factors, evaluated across the exposed population. Methods Bayesian multivariable regression analysis of retrospective population‐based cross‐sectional cohorts. Results We replicate positive and negative cognitive effects of commonly used medications in UK Biobank, and extend observed associations to two additional cohorts, the EPIC Norfolk, and the Caerphilly Prospective Cohort. We quantify the resultant cumulative impact at the population level given known patterns of prescribing and compare it with exemplar common diseases. Conclusion The cognitive side‐effects of commonly used drugs may have significant impact at the population level. Consideration should be given to a routine structured assessment of cognition in interventional trials and post‐market surveillance. |
| format | Article |
| id | doaj-art-7ac66493ad534ab5b1f26e87654b986e |
| institution | Kabale University |
| issn | 2162-3279 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj-art-7ac66493ad534ab5b1f26e87654b986e2025-01-29T13:36:40ZengWileyBrain and Behavior2162-32792025-01-01151n/an/a10.1002/brb3.70200The Cognitive Footprint of Medication UseMarta Suárez Pinilla0Charlotte R. Stoner1Martin Knapp2Parashkev Nachev3Martin Rossor4Clinical Neuroscience Laboratory, Center for Biomedical Technology Universidad Politécnica de Madrid Madrid SpainUCL Queen Square Institute of Neurology University College London London UKHealth Policy Department London School of Economics and Political Science London UKUCL Queen Square Institute of Neurology University College London London UKUCL Queen Square Institute of Neurology University College London London UKABSTRACT Introduction The cognitive side‐effects of medication are common, but often overlooked in practice, and not routinely considered in interventional trials or post‐market surveillance. The cognitive footprint of a medication seeks to quantify the impact of its cognitive effects based on magnitude, duration, and interaction with other factors, evaluated across the exposed population. Methods Bayesian multivariable regression analysis of retrospective population‐based cross‐sectional cohorts. Results We replicate positive and negative cognitive effects of commonly used medications in UK Biobank, and extend observed associations to two additional cohorts, the EPIC Norfolk, and the Caerphilly Prospective Cohort. We quantify the resultant cumulative impact at the population level given known patterns of prescribing and compare it with exemplar common diseases. Conclusion The cognitive side‐effects of commonly used drugs may have significant impact at the population level. Consideration should be given to a routine structured assessment of cognition in interventional trials and post‐market surveillance.https://doi.org/10.1002/brb3.70200medications | cognitive footprint | large‐scale cohorts | medication side effects | cognition |
| spellingShingle | Marta Suárez Pinilla Charlotte R. Stoner Martin Knapp Parashkev Nachev Martin Rossor The Cognitive Footprint of Medication Use Brain and Behavior medications | cognitive footprint | large‐scale cohorts | medication side effects | cognition |
| title | The Cognitive Footprint of Medication Use |
| title_full | The Cognitive Footprint of Medication Use |
| title_fullStr | The Cognitive Footprint of Medication Use |
| title_full_unstemmed | The Cognitive Footprint of Medication Use |
| title_short | The Cognitive Footprint of Medication Use |
| title_sort | cognitive footprint of medication use |
| topic | medications | cognitive footprint | large‐scale cohorts | medication side effects | cognition |
| url | https://doi.org/10.1002/brb3.70200 |
| work_keys_str_mv | AT martasuarezpinilla thecognitivefootprintofmedicationuse AT charlotterstoner thecognitivefootprintofmedicationuse AT martinknapp thecognitivefootprintofmedicationuse AT parashkevnachev thecognitivefootprintofmedicationuse AT martinrossor thecognitivefootprintofmedicationuse AT martasuarezpinilla cognitivefootprintofmedicationuse AT charlotterstoner cognitivefootprintofmedicationuse AT martinknapp cognitivefootprintofmedicationuse AT parashkevnachev cognitivefootprintofmedicationuse AT martinrossor cognitivefootprintofmedicationuse |